M20 Genomics launched the NATA spatial transcriptomics platform following the launch of the platform.
Published
Signal category
Products & Services
Quote
“Following the launch of NATA, we continue to share the technology and applications behind our spatial transcriptomics platform.”
— M20 Genomics team
Company
M20 Genomics
Pioneering life science with next-generation single-cell and spatial innovations
- Industry
- Biotechnology Research
- Location
- Singapore, SG
- Company size
- 11 employees
We are a rapidly growing life science technology company dedicated to pushing the boundaries of single-cell and spatial technologies. Our mission is to empower our customers by overcoming technological barriers in cutting-edge single-cell and spatial technologies, unraveling mysteries in life science, and driving advancements in disease diagnosis and treatment. With "M20 Seq" technology, we have pioneered the world's first high-throughput full-length single-cell technology sequencing using random primers, along with our VITA product line for single-cell transcriptome sequencing. In addition, our "M20 Spatial" technology, utilizing random primers and paired with our NATA spatial transcriptome product line, provides the first spatial full-transcriptome solution across various sample types.
Founded 2021